A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
NCT04669665
Completed
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/25/2023
Locations: Seelos Investigational Site, Orange, California +20 locations
Conditions: Depressive Disorder, Major, Suicidal
Register for Updates
Open Label Ketamine Treatment for Major Depressive Disorder in Veterans
NCT03053830
Completed
Medically healthy Veterans ages 21-75 that have been diagnosed with Depression will get up to 6 treatments of Ketamine infusions, weekly. After treatment is completed, follow up will occur at 1 month, 3 months, and 6 months after completion of infusions to evaluate the longer term effects of ketamine.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
09/15/2023
Locations: VA Healthcare System, West Haven, Connecticut
Conditions: Major Depressive Disorder
Register for Updates
Narcotic Free TIVA and Incidence of Unacceptable Movements Under Anesthesia During ACDF Surgery
NCT03643796
Completed
This study will help the investigators learn more about the best way to give anesthesia for these kinds of surgery. The investigators will be using 2 different groups of medications that is commonly used in ACDF surgery, one group has a Narcotic, and the other group does not. The investigators wish to test whether a narcotic free anesthetic will result in an overall safer surgery, better patient recovery, and satisfaction. The investigators think also that eliminating the Narcotic from the Anest... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/14/2023
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Anterior Cervical Discectomy and Fusion (ACDF)
Register for Updates
Treatment Resistant Depression (Pilot)
NCT01179009
Completed
Treatment resistant depression (TRD) is a major public health problem. Current therapeutic options for this patient population remain limited. With all available treatments, only a sub-set of those patients who achieve an antidepressant response are likely to achieve treatment-induced remission. The need for antidepressant medication that can provide both rapid and long lasting relief of TRD symptoms is widely recognized. There is new evidence that drugs that block NMDA glutamate receptors (NMDA... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/11/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Depressive Disorder, Treatment-Resistant
Register for Updates
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
NCT03113968
Completed
The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
09/01/2023
Locations: Yale School of Medicine, New Haven, Connecticut +4 locations
Conditions: Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine, Psychiatric Disorder, Depression, Major Depressive Disorder, Major Depressive Episode, Unipolar Depression
Register for Updates
Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT06021756
Active Not Recruiting
The primary objective is to determine the tolerability and efficacy of a low-dose ketamine infusion for the treatment of Levodopa-Induced dyskinesias (LID), both acutely and during post-infusion evaluation (week 2-6), as measured by a change in patient diaries of dyskinesia and the UDysRS. Secondary objectives include observing the effects of ketamine on various symptoms of Parkinson's disease and Levodopa side effects. This includes the duration of "off," "on without dyskinesia," and "troubleso... Read More
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
08/27/2023
Locations: Scott J Sherman, Tucson, Arizona
Conditions: Levodopa-Induced Dyskinesia, Parkinson's Disease
Register for Updates
Intranasal Ketamine for Suicidal Ideation in Veterans
NCT03788694
Withdrawn
The objective of the current study is to investigate the safety, efficacy, and feasibility of multiple doses of intranasal (IN) ketamine for suicidal ideation Veterans.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
08/03/2023
Locations: James J. Peters VA Medical Center, Bronx, New York
Conditions: Suicidal Ideation
Register for Updates
Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy
NCT03613792
Withdrawn
This randomized controlled pilot clinical trial will enroll patients undergoing dynamic flexible bronchoscopy will be randomized to receive one of the two anesthetic combinations described above. The study will determine if there is a difference when considering patient and physician and satisfaction when performing DFB. Also, safety and efficacy of the two pharmacological combinations (fentanyl + midazolam and remifentanil + ketamine) used will be evaluated.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/25/2023
Locations: Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts
Conditions: Bronchoscopy
Register for Updates
Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort
NCT05855876
Recruiting
The purpose of this study is to examine measures of GrimAge clock in SOF members undergoing treatment for PTSD/TBI using CSB.
Gender:
ALL
Ages:
Between 40 years and 60 years
Trial Updated:
07/13/2023
Locations: Stella Center, Westmont, Illinois
Conditions: Post-Traumatic Stress Disorder, Traumatic Brain Injury
Register for Updates
Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department
NCT01900847
Terminated
Our goal is to study whether giving people low dose ketamine along with morphine when they come to the Emergency Department will help their pain more than giving morphine by itself. There have been many studies showing that low dose ketamine is safe and effective for pain control. Ketamine is frequently used for pain control in ambulances and helicopters transporting injured patients to the hospital and has also been used for pain control in people who have just had surgery. The investigators wo... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/11/2023
Locations: University of Arizona Health Network University Campus 1501 North Campbell Ave, Tucson, Arizona
Conditions: Acute Pain
Register for Updates
Low-Dose Ketamine in Children With ADNP Syndrome
NCT04388774
Completed
This is a Phase 2A, single dose, open-label study to evaluate the safety, tolerability, and efficacy of a low-dose, 40-minute infusion into the veins (intravenous infusion or "IV") of ketamine in children with ADNP syndrome (Activity-Dependent Neuroprotective Protein). The study team will enroll 10 participants, ages 5 to 12, at Mount Sinai. The study participation is expected to last 4 weeks and will include 5 scheduled clinic visits in order to complete safety monitoring, clinical assessments,... Read More
Gender:
ALL
Ages:
Between 5 years and 12 years
Trial Updated:
07/05/2023
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: ADNP Syndrome
Register for Updates
Ketamine in Borderline Personality Disorder
NCT03395314
Terminated
The purpose of this study is to test the potential of the rapid-acting anti-depressant ketamine to decrease suicidality in Borderline Personality Disorder (BPD). The rate of completed suicide in BPD is similar to that of depression or schizophrenia. There is currently no specific medication treatment for BPD. Ketamine is an FDA-approved anesthetic agent that has been shown to rapidly decrease suicidality and improve mood in people with Major Depressive Disorder (MDD). Though symptoms overlap,... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
05/31/2023
Locations: Connecticut Mental Health Center, New Haven, Connecticut +1 locations
Conditions: Borderline Personality Disorder
Register for Updates